Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
AstraZeneca completes Amolyt Pharma acquisition
Eneboparatide therapeutic peptide binds to the parathyroid hormone receptor. Credit: Prostock-studio/Shutterstock. AstraZeneca has closed the acquisition of Amolyt Pharma, a company specialising in treatments for
July 16, 2024